About H2S Bio
Scientific depth. Executive perspective. Practical decisions.
H2S Bio is a founder-led biotech advisory firm built around a single principle: rigorous scientific judgment applied at the moments that matter most. The firm integrates expertise across discovery biology, DMPK and ADME, translational science, nonclinical development, and regulatory strategy – bringing a unified scientific perspective to decisions that typically require assembling multiple specialists.
This breadth is deliberate. Drug programs do not fail in one dimension – they fail at the intersection of science, strategy, and timing. H2S Bio is structured to operate at that intersection: helping biotechs, investors, and development teams think clearly, move decisively, and avoid the downstream consequences of early gaps in reasoning.
Engagements are designed to be focused and high-impact – from rapid program diagnostics and defined advisory projects to recurring executive guidance and independent technical assessments. The work is hands-on, founder-direct, and calibrated to what each program actually needs.
How We Work
Integrate Early
We engage at the inflection points that shape downstream outcomes, before decisions become irreversible.
Focus on the Decision
Every engagement is organized around the question that matters most, not the data that’s easiest to generate.
Make Strategy Executable
Recommendations are grounded in operational reality, so science translates directly into plans teams can act on.
Founder
Herve Aloysius, PhD
Herve Aloysius, PhD brings 24+ years of pharmaceutical and biotechnology experience across discovery, DMPK/ADME, translational science, nonclinical development, regulatory strategy, and cross-functional leadership. He has supported 8 INDs and 4 NDAs.
Let’s discuss your program.
H2S Bio provides focused scientific and strategic support at critical discovery and development decisions.